カテゴリ： Allied Market Research, 世界, 医療/バイオ

卵巣がん治療薬のグローバル市場（2021〜2031）：化学治療、標的治療、その他

■ 英語タイトル：Global Ovarian Cancer Drugs Market By Therapy (Chemotherapy, Targeted Therapy, Others), By Distribution Channel (Hospital Pharmacy, Drug Stores and Retail Pharmacy, Online Providers): Global Opportunity Analysis and Industry Forecast, 2021-2031

調査会社Allied Market Research社が発行したリサーチレポート（データ管理コード：ALD23FB242）■ 発行会社/調査会社：Allied Market Research
■ 商品コード：ALD23FB242
■ 発行日：2022年10月
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：189
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後24時間以内）
■ 販売価格オプション（消費税別）
Online Only（1名閲覧、印刷不可）USD3,570 ⇒換算￥542,640見積依頼/購入/質問フォーム
Single User（1名閲覧）USD5,730 ⇒換算￥870,960見積依頼/購入/質問フォーム
Enterprise User（閲覧人数無制限）USD9,600 ⇒換算￥1,459,200見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Allied Market Research社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[卵巣がん治療薬のグローバル市場（2021〜2031）：化学治療、標的治療、その他]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

Allied Market Research社の本市場調査レポートでは、2021年に2,283.8百万ドルであった世界の卵巣がん治療薬市場規模が、2031年までに5,063.59百万ドルに到達し、2022年から2031年にかけてCAGR（年平均成長率）8.4%で成長すると予測しています。本レポートは、卵巣がん治療薬の世界市場を総合的に調査・分析した資料であり、イントロダクション、エグゼクティブサマリー、市場概要、治療別（化学治療、標的治療、その他）分析、流通チャネル別（病院薬局、ドラッグストア・小売薬局、オンライン供給者）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米・中東・アフリカ）分析、企業状況、企業情報などを掲載しています。また、本レポートは、Abbvie Inc、Pfizer, Inc.、Merck KGaA、AstraZeneca、F. Hoffmann-La Roche AG、Clovis Oncology、Amgen Inc.、Johnson & Johnson Services, Inc.などの企業情報を含んでいます。
・イントロダクション
・エグゼクティブサマリー
・市場概要
・世界の卵巣がん治療薬市場規模：治療別
- 化学治療における市場規模
- 標的治療における市場規模
- その他における市場規模
・世界の卵巣がん治療薬市場規模：流通チャネル別
- 病院薬局チャネルの市場規模
- ドラッグストア・小売薬局チャネルの市場規模
- オンライン供給者チャネルの市場規模
・世界の卵巣がん治療薬市場規模：地域別
- 北米の卵巣がん治療薬市場規模
- ヨーロッパの卵巣がん治療薬市場規模
- アジア太平洋の卵巣がん治療薬市場規模
- 中南米・中東・アフリカの卵巣がん治療薬市場規模
・企業状況
・企業情報

世界の卵巣がん治療薬市場は、2021年に22億8,380万ドルを占め、2022年から2031年までの年平均成長率は8.4%となり、2031年には50億6,359万ドルに達すると予測されています。

卵巣がんは卵巣にできる細胞の増殖です。この細胞は急速に増殖し、健康な体組織を侵し破壊します。女性の生殖器官には2つの卵巣があり、子宮の両側に1つずつあります。それぞれの卵巣はアーモンドほどの大きさで、プロゲステロンとエストロゲンというホルモンとともに卵子（卵巣）を産みます。卵巣がんの治療には通常、手術と化学療法が行われます。卵巣がんの徴候や症状には、腹部の膨満感や腫れ、食事をしてもすぐに満腹感を感じる、体重減少、骨盤周辺の不快感、疲労感、背部痛、便習慣の変化、頻尿などがあります。

卵巣がん治療薬市場は、女性の高齢化、卵巣がんの有病率の上昇、革新的な医薬品の発売、医療費の増加、政府の支援強化などにより、予測期間中に大きな成長が見込まれています。加えて、各社の研究開発投資の増加、強力なパイプライン候補の存在、発展途上地域における疾病予防に対する社会的意識の高まりが、市場の成長をさらに促進します。しかし、医薬品開発には高いコストがかかり、失敗の恐れもあるため、市場の成長は阻害されると予想されます。一方、がん研究の進歩や個別化医療のアプローチは、卵巣がん治療薬市場に大きな成長機会をもたらすと期待されています。

卵巣がん治療薬市場は、治療法、流通チャネル、地域によって区分されます。治療法によって、市場は化学療法、標的療法、その他に分類されます。流通チャネル別では、病院薬局、ドラッグストアや小売薬局、オンラインプロバイダーに分類されます。地域別では、北米（米国、カナダ、メキシコ）、欧州（ドイツ、フランス、英国、イタリア、スペイン、その他の欧州地域）、アジア太平洋地域（日本、中国、オーストラリア、インド、韓国、その他のアジア太平洋地域）、LAMEA（ブラジル、南アフリカ、サウジアラビア、その他のLAMEA地域）に市場を分けて分析しています。

本レポートは、世界の卵巣がん治療薬市場で事業を展開する主要企業の包括的な分析を提供します。本レポートに掲載されている主要企業には、AbbVie、Pfizer, Inc.、Merck Kagan、AstraZeneca、F. Hoffmann-La Roche AG、Johnson & Johnson Services, Inc.、GlaxoSmithKline Plc、Boehringer Ingelheim International GmbH、Clovis Oncology、Amgenが含まれます。

〈ステークホルダーにとっての主なメリット〉
・本レポートは、2021年から2031年までの世界の卵巣がん治療薬市場分析の市場セグメント、現在の動向、予測、ダイナミクスを定量的に分析し、世界の卵巣がん治療薬市場の有力な機会を特定します。
・主要な促進要因、阻害要因、機会に関する情報とともに市場調査を提供します。
・ポーターのファイブフォース分析により、バイヤーとサプライヤーの潜在力を明らかにし、ステークホルダーが利益重視のビジネス決定を行い、サプライヤーとバイヤーのネットワークを強化できるようにします。
・世界の卵巣がん治療薬市場のセグメンテーションを詳細に分析することで、市場機会を見極めることができます。
・各地域の主要国について、世界市場に対する収益貢献度をマッピングしています。
・市場プレイヤーのポジショニングはベンチマーキングを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
・卵巣がん治療薬の地域別、世界の市場動向、主要企業、市場セグメント、応用分野、市場成長戦略などの分析を掲載しています。

〈主要市場セグメント〉
治療法別
化学療法
標的療法
その他

販売チャネル別
病院薬局
ドラッグストア・小売薬局
オンラインプロバイダー

地域別
・北米
米国
カナダ
メキシコ
・ヨーロッパ
ドイツ
フランス
イギリス
イタリア
スペイン
その他のヨーロッパ
・アジア太平洋
日本
中国
オーストラリア
インド
韓国
その他のアジア太平洋地域
・LAMEA
ブラジル
サウジアラビア
南アフリカ
その他のLAMEA地域

〈主要市場プレイヤー〉
Abbvie Inc
Pfizer, Inc.
Merck KGaA
AstraZeneca
F. Hoffmann-La Roche AG
Clovis Oncology
Amgen Inc.
Johnson & Johnson Services, Inc.
Boehringer Ingelheim International GmbH
GlaxoSmithKline plc

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY
4.1 Overview
4.1.1 Market size and forecast
4.2 Chemotherapy
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market share analysis by country
4.3 Targeted Therapy
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market share analysis by country
4.3.4 Targeted Therapy Global Ovarian Cancer Drugs Market by Drug Class
4.4 Others
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market share analysis by country
CHAPTER 5: GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL
5.1 Overview
5.1.1 Market size and forecast
5.2 Hospital Pharmacy
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market share analysis by country
5.3 Drug Stores and Retail Pharmacy
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market share analysis by country
5.4 Online Providers
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market share analysis by country
CHAPTER 6: GLOBAL OVARIAN CANCER DRUGS MARKET, BY REGION
6.1 Overview
6.1.1 Market size and forecast
6.2 North America
6.2.1 Key trends and opportunities
6.2.2 North America Market size and forecast, by Therapy
6.2.3 North America Market size and forecast, by Distribution Channel
6.2.4 North America Market size and forecast, by country
6.2.4.1 U.S.
6.2.4.1.1 Key market trends, growth factors and opportunities
6.2.4.1.2 Market size and forecast, by Therapy
6.2.4.1.3 Market size and forecast, by Distribution Channel
6.2.4.2 Canada
6.2.4.2.1 Key market trends, growth factors and opportunities
6.2.4.2.2 Market size and forecast, by Therapy
6.2.4.2.3 Market size and forecast, by Distribution Channel
6.2.4.3 Mexico
6.2.4.3.1 Key market trends, growth factors and opportunities
6.2.4.3.2 Market size and forecast, by Therapy
6.2.4.3.3 Market size and forecast, by Distribution Channel
6.3 Europe
6.3.1 Key trends and opportunities
6.3.2 Europe Market size and forecast, by Therapy
6.3.3 Europe Market size and forecast, by Distribution Channel
6.3.4 Europe Market size and forecast, by country
6.3.4.1 Germany
6.3.4.1.1 Key market trends, growth factors and opportunities
6.3.4.1.2 Market size and forecast, by Therapy
6.3.4.1.3 Market size and forecast, by Distribution Channel
6.3.4.2 France
6.3.4.2.1 Key market trends, growth factors and opportunities
6.3.4.2.2 Market size and forecast, by Therapy
6.3.4.2.3 Market size and forecast, by Distribution Channel
6.3.4.3 UK
6.3.4.3.1 Key market trends, growth factors and opportunities
6.3.4.3.2 Market size and forecast, by Therapy
6.3.4.3.3 Market size and forecast, by Distribution Channel
6.3.4.4 Italy
6.3.4.4.1 Key market trends, growth factors and opportunities
6.3.4.4.2 Market size and forecast, by Therapy
6.3.4.4.3 Market size and forecast, by Distribution Channel
6.3.4.5 Spain
6.3.4.5.1 Key market trends, growth factors and opportunities
6.3.4.5.2 Market size and forecast, by Therapy
6.3.4.5.3 Market size and forecast, by Distribution Channel
6.3.4.6 Rest of Europe
6.3.4.6.1 Key market trends, growth factors and opportunities
6.3.4.6.2 Market size and forecast, by Therapy
6.3.4.6.3 Market size and forecast, by Distribution Channel
6.4 Asia-Pacific
6.4.1 Key trends and opportunities
6.4.2 Asia-Pacific Market size and forecast, by Therapy
6.4.3 Asia-Pacific Market size and forecast, by Distribution Channel
6.4.4 Asia-Pacific Market size and forecast, by country
6.4.4.1 Japan
6.4.4.1.1 Key market trends, growth factors and opportunities
6.4.4.1.2 Market size and forecast, by Therapy
6.4.4.1.3 Market size and forecast, by Distribution Channel
6.4.4.2 China
6.4.4.2.1 Key market trends, growth factors and opportunities
6.4.4.2.2 Market size and forecast, by Therapy
6.4.4.2.3 Market size and forecast, by Distribution Channel
6.4.4.3 Australia
6.4.4.3.1 Key market trends, growth factors and opportunities
6.4.4.3.2 Market size and forecast, by Therapy
6.4.4.3.3 Market size and forecast, by Distribution Channel
6.4.4.4 India
6.4.4.4.1 Key market trends, growth factors and opportunities
6.4.4.4.2 Market size and forecast, by Therapy
6.4.4.4.3 Market size and forecast, by Distribution Channel
6.4.4.5 South Korea
6.4.4.5.1 Key market trends, growth factors and opportunities
6.4.4.5.2 Market size and forecast, by Therapy
6.4.4.5.3 Market size and forecast, by Distribution Channel
6.4.4.6 Rest of Asia-Pacific
6.4.4.6.1 Key market trends, growth factors and opportunities
6.4.4.6.2 Market size and forecast, by Therapy
6.4.4.6.3 Market size and forecast, by Distribution Channel
6.5 LAMEA
6.5.1 Key trends and opportunities
6.5.2 LAMEA Market size and forecast, by Therapy
6.5.3 LAMEA Market size and forecast, by Distribution Channel
6.5.4 LAMEA Market size and forecast, by country
6.5.4.1 Brazil
6.5.4.1.1 Key market trends, growth factors and opportunities
6.5.4.1.2 Market size and forecast, by Therapy
6.5.4.1.3 Market size and forecast, by Distribution Channel
6.5.4.2 Saudi Arabia
6.5.4.2.1 Key market trends, growth factors and opportunities
6.5.4.2.2 Market size and forecast, by Therapy
6.5.4.2.3 Market size and forecast, by Distribution Channel
6.5.4.3 South Africa
6.5.4.3.1 Key market trends, growth factors and opportunities
6.5.4.3.2 Market size and forecast, by Therapy
6.5.4.3.3 Market size and forecast, by Distribution Channel
6.5.4.4 Rest of LAMEA
6.5.4.4.1 Key market trends, growth factors and opportunities
6.5.4.4.2 Market size and forecast, by Therapy
6.5.4.4.3 Market size and forecast, by Distribution Channel
CHAPTER 7: COMPANY LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Key developments
CHAPTER 8: COMPANY PROFILES
8.1 F. Hoffmann-La Roche AG
8.1.1 Company overview
8.1.2 Company snapshot
8.1.3 Operating business segments
8.1.4 Product portfolio
8.1.5 Business performance
8.1.6 Key strategic moves and developments
8.2 Johnson & Johnson Services, Inc.
8.2.1 Company overview
8.2.2 Company snapshot
8.2.3 Operating business segments
8.2.4 Product portfolio
8.2.5 Business performance
8.2.6 Key strategic moves and developments
8.3 GlaxoSmithKline Plc
8.3.1 Company overview
8.3.2 Company snapshot
8.3.3 Operating business segments
8.3.4 Product portfolio
8.3.5 Business performance
8.3.6 Key strategic moves and developments
8.4 Boehringer Ingelheim International GmbH
8.4.1 Company overview
8.4.2 Company snapshot
8.4.3 Operating business segments
8.4.4 Product portfolio
8.4.5 Business performance
8.4.6 Key strategic moves and developments
8.5 Clovis Oncology
8.5.1 Company overview
8.5.2 Company snapshot
8.5.3 Operating business segments
8.5.4 Product portfolio
8.5.5 Business performance
8.5.6 Key strategic moves and developments
8.6 Abbvie Inc
8.6.1 Company overview
8.6.2 Company snapshot
8.6.3 Operating business segments
8.6.4 Product portfolio
8.6.5 Business performance
8.6.6 Key strategic moves and developments
8.7 Pfizer, Inc.
8.7.1 Company overview
8.7.2 Company snapshot
8.7.3 Operating business segments
8.7.4 Product portfolio
8.7.5 Business performance
8.7.6 Key strategic moves and developments
8.8 Merck KGaA
8.8.1 Company overview
8.8.2 Company snapshot
8.8.3 Operating business segments
8.8.4 Product portfolio
8.8.5 Business performance
8.8.6 Key strategic moves and developments
8.9 AstraZeneca
8.9.1 Company overview
8.9.2 Company snapshot
8.9.3 Operating business segments
8.9.4 Product portfolio
8.9.5 Business performance
8.9.6 Key strategic moves and developments
8.10 Amgen Inc.
8.10.1 Company overview
8.10.2 Company snapshot
8.10.3 Operating business segments
8.10.4 Product portfolio
8.10.5 Business performance
8.10.6 Key strategic moves and developments

LIST OF TABLES
TABLE 1. GLOBAL GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
TABLE 2. GLOBAL OVARIAN CANCER DRUGS MARKET FOR CHEMOTHERAPY, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 3. GLOBAL OVARIAN CANCER DRUGS MARKET FOR CHEMOTHERAPY, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 4. GLOBAL OVARIAN CANCER DRUGS MARKET FOR TARGETED THERAPY, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 5. GLOBAL OVARIAN CANCER DRUGS MARKET FOR TARGETED THERAPY, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 6. GLOBAL TARGETED THERAPY GLOBAL OVARIAN CANCER DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 7. GLOBAL OVARIAN CANCER DRUGS MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 8. GLOBAL OVARIAN CANCER DRUGS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 9. GLOBAL GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 10. GLOBAL OVARIAN CANCER DRUGS MARKET FOR HOSPITAL PHARMACY, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 11. GLOBAL OVARIAN CANCER DRUGS MARKET FOR HOSPITAL PHARMACY, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 12. GLOBAL OVARIAN CANCER DRUGS MARKET FOR DRUG STORES AND RETAIL PHARMACY, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 13. GLOBAL OVARIAN CANCER DRUGS MARKET FOR DRUG STORES AND RETAIL PHARMACY, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 14. GLOBAL OVARIAN CANCER DRUGS MARKET FOR ONLINE PROVIDERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 15. GLOBAL OVARIAN CANCER DRUGS MARKET FOR ONLINE PROVIDERS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 16. GLOBAL OVARIAN CANCER DRUGS MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 17. NORTH AMERICA GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
TABLE 18. NORTH AMERICA GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 19. NORTH AMERICA GLOBAL OVARIAN CANCER DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 20. U.S. GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
TABLE 21. U.S. GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 22. CANADA GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
TABLE 23. CANADA GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 24. MEXICO GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
TABLE 25. MEXICO GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 26. EUROPE GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
TABLE 27. EUROPE GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 28. EUROPE GLOBAL OVARIAN CANCER DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 29. GERMANY GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
TABLE 30. GERMANY GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 31. FRANCE GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
TABLE 32. FRANCE GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 33. UK GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
TABLE 34. UK GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 35. ITALY GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
TABLE 36. ITALY GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 37. SPAIN GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
TABLE 38. SPAIN GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 39. REST OF EUROPE GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
TABLE 40. REST OF EUROPE GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 41. ASIA-PACIFIC GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
TABLE 42. ASIA-PACIFIC GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 43. ASIA-PACIFIC GLOBAL OVARIAN CANCER DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 44. JAPAN GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
TABLE 45. JAPAN GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 46. CHINA GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
TABLE 47. CHINA GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 48. AUSTRALIA GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
TABLE 49. AUSTRALIA GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 50. INDIA GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
TABLE 51. INDIA GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 52. SOUTH KOREA GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
TABLE 53. SOUTH KOREA GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 54. REST OF ASIA-PACIFIC GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
TABLE 55. REST OF ASIA-PACIFIC GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 56. LAMEA GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
TABLE 57. LAMEA GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 58. LAMEA GLOBAL OVARIAN CANCER DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 59. BRAZIL GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
TABLE 60. BRAZIL GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 61. SAUDI ARABIA GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
TABLE 62. SAUDI ARABIA GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 63. SOUTH AFRICA GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
TABLE 64. SOUTH AFRICA GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 65. REST OF LAMEA GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
TABLE 66. REST OF LAMEA GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 67.F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT
TABLE 68.F. HOFFMANN-LA ROCHE AG: OPERATING SEGMENTS
TABLE 69.F. HOFFMANN-LA ROCHE AG: PRODUCT PORTFOLIO
TABLE 70.F. HOFFMANN-LA ROCHE AG: NET SALES
TABLE 71.F. HOFFMANN-LA ROCHE AG: KEY STRATERGIES
TABLE 72.JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT
TABLE 73.JOHNSON & JOHNSON SERVICES, INC.: OPERATING SEGMENTS
TABLE 74.JOHNSON & JOHNSON SERVICES, INC.: PRODUCT PORTFOLIO
TABLE 75.JOHNSON & JOHNSON SERVICES, INC.: NET SALES
TABLE 76.JOHNSON & JOHNSON SERVICES, INC.: KEY STRATERGIES
TABLE 77.GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
TABLE 78.GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
TABLE 79.GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
TABLE 80.GLAXOSMITHKLINE PLC: NET SALES
TABLE 81.GLAXOSMITHKLINE PLC: KEY STRATERGIES
TABLE 82.BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT
TABLE 83.BOEHRINGER INGELHEIM INTERNATIONAL GMBH: OPERATING SEGMENTS
TABLE 84.BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCT PORTFOLIO
TABLE 85.BOEHRINGER INGELHEIM INTERNATIONAL GMBH: NET SALES
TABLE 86.BOEHRINGER INGELHEIM INTERNATIONAL GMBH: KEY STRATERGIES
TABLE 87.CLOVIS ONCOLOGY: COMPANY SNAPSHOT
TABLE 88.CLOVIS ONCOLOGY: OPERATING SEGMENTS
TABLE 89.CLOVIS ONCOLOGY: PRODUCT PORTFOLIO
TABLE 90.CLOVIS ONCOLOGY: NET SALES
TABLE 91.CLOVIS ONCOLOGY: KEY STRATERGIES
TABLE 92.ABBVIE INC: COMPANY SNAPSHOT
TABLE 93.ABBVIE INC: OPERATING SEGMENTS
TABLE 94.ABBVIE INC: PRODUCT PORTFOLIO
TABLE 95.ABBVIE INC: NET SALES
TABLE 96.ABBVIE INC: KEY STRATERGIES
TABLE 97.PFIZER, INC.: COMPANY SNAPSHOT
TABLE 98.PFIZER, INC.: OPERATING SEGMENTS
TABLE 99.PFIZER, INC.: PRODUCT PORTFOLIO
TABLE 100.PFIZER, INC.: NET SALES
TABLE 101.PFIZER, INC.: KEY STRATERGIES
TABLE 102.MERCK KGAA: COMPANY SNAPSHOT
TABLE 103.MERCK KGAA: OPERATING SEGMENTS
TABLE 104.MERCK KGAA: PRODUCT PORTFOLIO
TABLE 105.MERCK KGAA: NET SALES
TABLE 106.MERCK KGAA: KEY STRATERGIES
TABLE 107.ASTRAZENECA: COMPANY SNAPSHOT
TABLE 108.ASTRAZENECA: OPERATING SEGMENTS
TABLE 109.ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 110.ASTRAZENECA: NET SALES
TABLE 111.ASTRAZENECA: KEY STRATERGIES
TABLE 112.AMGEN INC.: COMPANY SNAPSHOT
TABLE 113.AMGEN INC.: OPERATING SEGMENTS
TABLE 114.AMGEN INC.: PRODUCT PORTFOLIO
TABLE 115.AMGEN INC.: NET SALES
TABLE 116.AMGEN INC.: KEY STRATERGIES

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 皮膚がん治療のグローバル市場（2021〜2031）：黒色腫、非黒色腫
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(ALD23FB242 )"卵巣がん治療薬のグローバル市場（2021〜2031）：化学治療、標的治療、その他" (英文：Global Ovarian Cancer Drugs Market By Therapy (Chemotherapy, Targeted Therapy, Others), By Distribution Channel (Hospital Pharmacy, Drug Stores and Retail Pharmacy, Online Providers): Global Opportunity Analysis and Industry Forecast, 2021-2031)はAllied Market Research社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。